Cytokinetics Incorporated

24.16-0.0300-0.12%Vol 595.62K1Y Perf 72.57%
Apr 9th, 2021 16:00 DELAYED
BID24.14 ASK24.15
Open23.98 Previous Close24.19
Pre-Market- After-Market24.16
 - -  - -%
Target Price
35.00 
Analyst Rating
Strong Buy 1.10
Potential %
44.87 
Finscreener Ranking
★★     46.59
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
     40.27
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★     53.34
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap1.72B 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
64.95 
Earnings Date
5th May 2021

Today's Price Range

23.5424.52

52W Range

13.0830.14

5 Year PE Ratio Range

-6.2050.60

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-1.15%
1 Month
22.64%
3 Months
12.11%
6 Months
58.32%
1 Year
72.57%
3 Years
230.96%
5 Years
213.36%
10 Years
179.63%

TickerPriceChg.Chg.%
CYTK24.16-0.0300-0.12
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Financial StrengthValueIndustryS&P 500US Markets
15.00
15.20
0.55
1.23
-2.30
Leverage Ratio 27.60
ProfitabilityValueIndustryS&P 500US Markets
-
-158.70
-155.40
-476.90
-
RevenueValueIndustryS&P 500US Markets
52.00M
0.73
47.53
-1.68
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.48-0.62-29.17
Q03 2020-0.59-0.0591.53
Q02 2020-0.57-0.68-19.30
Q01 2020-0.50-0.66-32.00
Q04 2019-0.42-0.52-23.81
Q03 2019-0.56-0.5010.71
Q02 2019-0.53-0.56-5.66
Q01 2019-0.47-0.54-14.89
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.59-118.52Negative
6/2021 QR-0.63-65.79Negative
12/2021 FY-2.48-34.05Negative
12/2022 FY-2.99-33.48Negative
Next Report Date5th May 2021
Estimated EPS Next Report-0.59
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume595.62K
Shares Outstanding71.11M
Trades Count6.46K
Dollar Volume11.81M
Avg. Volume928.71K
Avg. Weekly Volume699.13K
Avg. Monthly Volume911.33K
Avg. Quarterly Volume924.27K

Cytokinetics Incorporated (NASDAQ: CYTK) stock closed at 24.16 per share at the end of the most recent trading day (a -0.12% change compared to the prior day closing price) with a volume of 598.05K shares and market capitalization of 1.72B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 156 people. Cytokinetics Incorporated CEO is Robert I. Blum.

The one-year performance of Cytokinetics Incorporated stock is 72.57%, while year-to-date (YTD) performance is 16.27%. CYTK stock has a five-year performance of 213.36%. Its 52-week range is between 13.08 and 30.14, which gives CYTK stock a 52-week price range ratio of 64.95%

Cytokinetics Incorporated currently has a PE ratio of -12.10, a price-to-book (PB) ratio of 14.59, a price-to-sale (PS) ratio of 34.36, a price to cashflow ratio of 167.80, a PEG ratio of 2.32, a ROA of -29.97%, a ROC of -50.33% and a ROE of -250.88%. The company’s profit margin is -%, its EBITDA margin is -155.40%, and its revenue ttm is $52.00 Million , which makes it $0.73 revenue per share.

Of the last four earnings reports from Cytokinetics Incorporated, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.59 for the next earnings report. Cytokinetics Incorporated’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for Cytokinetics Incorporated is Strong Buy (1.1), with a target price of $35, which is +44.87% compared to the current price. The earnings rating for Cytokinetics Incorporated stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cytokinetics Incorporated has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cytokinetics Incorporated has a Buy technical analysis rating based on Technical Indicators (ADX : 9.05, ATR14 : 1.40, CCI20 : -50.45, Chaikin Money Flow : -0.34, MACD : -0.52, Money Flow Index : 50.43, ROC : -4.56, RSI : 46.04, STOCH (14,3) : 35.06, STOCH RSI : 1.00, UO : 42.69, Williams %R : -64.94), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cytokinetics Incorporated in the last 12-months were: B. Lynne Parshall (Option Excercise at a value of $387 993), B. Lynne Parshall (Sold 63 331 shares of value $1 734 830 ), Ching Jaw (Option Excercise at a value of $464 100), Ching Jaw (Sold 52 500 shares of value $1 450 000 ), David W. Cragg (Option Excercise at a value of $156 994), Edward M. Kaye (Option Excercise at a value of $152 200), Edward M. Kaye (Sold 20 000 shares of value $600 000 ), Fady Ibraham Malik (Option Excercise at a value of $117 750), Fady Ibraham Malik (Sold 22 854 shares of value $461 364 ), John T. Henderson (Option Excercise at a value of $162 242), John T. Henderson (Sold 4 591 shares of value $112 259 ), L. Patrick Gage (Option Excercise at a value of $56 194), Leonard Patrick Gage (Option Excercise at a value of $284 986), Leonard Patrick Gage (Sold 28 055 shares of value $625 878 ), Mark A. Schlossberg (Option Excercise at a value of $140 600), Mark A. Schlossberg (Sold 20 000 shares of value $480 728 ), Robert I. Blum (Option Excercise at a value of $1 564 902), Robert I. Blum (Sold 135 000 shares of value $2 811 876 ), Sandford Drexel Smith (Option Excercise at a value of $734 982), Sandford Drexel Smith (Sold 126 192 shares of value $3 120 443 ), Santo J. Costa (Option Excercise at a value of $1 000 817), Santo J. Costa (Sold 123 330 shares of value $2 781 017 ), Wendell D. Wierenga (Option Excercise at a value of $204 780), Wendell D. Wierenga (Sold 19 998 shares of value $319 968 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (80.00 %)
4 (80.00 %)
3 (75.00 %)
Moderate Buy
1 (20.00 %)
1 (20.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
1 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.10
Strong Buy
1.10
Strong Buy
1.50

Cytokinetics Incorporated

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatment for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility.

CEO: Robert I. Blum

Telephone: +1 650 624-3000

Address: 280 East Grand Avenue, South San Francisco 94080, CA, US

Number of employees: 156

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

48%52%

News

Stocktwits